Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Daniel Catenacci, MD, of the University of Chicago, Chicago, IL, discusses the phase IIa PANGEA study (NCT02213289), a precision medicine trial in gastroesophageal adenocarcinoma, evaluating biomarkers for antibody therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.